BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Durham, NC. Its latest filed balance sheet (2025-12-31) shows total assets of $465 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.0 out of ten, 9 of 9 metrics filed: past 6.1 out of ten, present 5.6 out of ten, future 6.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.5 out of ten. +47.6% a year over 10 filed years; profitable in 1 of 10. 65th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 4.4 out of ten. Share count grew 5.5% a year. 0% of cash flow returned. Insiders: 10 sales, 0 purchases. 44th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.2 out of ten. Leverage 123%: owes 123¢ per asset dollar. 62nd percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.7 out of ten. top 14% of 102 in its family; net margin 30.2%. 86th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 2.8 out of ten. bottom 27% of 108 in its family for leadership. 27th percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 5.5 out of ten. top 45% of 92 in its family for room to expand. 55th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 6.4 out of ten. top 36% of 100 in its family for growth drivers. 64th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 7.5 out of ten. top 25% of 72 in its family for expectations against reality. 75th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-09-02. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: ORLADEYO 68%, License 28%, Other Income From Contract With Customer 3%, Collaborative and Other Research and Development 1%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Stonehouse, Jon P (Chief Executive Officer); Gayer, Charles K (President and CCO); Ghias, Babar (Chief Financial Officer); Barnes, Alane P (Chief Legal Officer); Menon, Sandeep (Chief R&D Officer); Dullinger, Ronald (Chief Commercial Officer); Frank, Steven (director); Mckee, Amy E (director); Milano, Vincent (director); Milne, Jill C. (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.